Growing PAH Cases Drive Need For Advanced Therapeutic Solutions: A Key Driver Powering VELETRI Market Growth In 2025

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current VELETRI Market Size and Its Estimated Growth Rate?
The market size of VELETRI has been experiencing robust growth in the past few years. It is projected to rise from $1.34 billion in 2024 to $1.45 billion in 2025, with a compound annual growth rate (CAGR) of 7.9%. The historic period's growth can be ascribed to factors such as the increasing incidence of pulmonary arterial hypertension (PAH), heightened awareness of PAH, an expanding aging population, a global increase due to shifts in lifestyle, and a rise in healare spending.

The market size of VELETRI is anticipated to experience robust growth in the upcoming years. It is predicted to expand to $1.95 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. Multiple factors contribute to this growth in the forecasted period, including an increase in the occurrence of venous diseases, escalating awareness and early detection, increasing expenditure on chronic illnesses, enhancements in healare infrastructure, and an expanding patient population. Significant trends during the forecast period encompass technological innovations, partnerships between pharmaceutical firms and research bodies, a strong pipeline of clinical research activities, an upsurge in R&D endeavours, and the introduction of biosimilars and generics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21314

How Are Emerging Segments Shaping the VELETRI Market Landscape?
The veletri market covered in this report is segmented -

1) By Product Type: Injectable, Inhalation
2) By Application: Pulmonary Arterial Hypertension, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Injectable: Intravenous (IV) Injection, Subcutaneous (SC) Injection
2) By Inhalation: Nebulized Inhalation, Dry Powder Inhalation

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21314&type=smp

Which Growth Factors Are Influencing VELETRI Market Expansion?
The VELETRI market anticipates growth driven by the escalating prevalence of pulmonary arterial hypertension (PAH), a rare, progressive disease causing high blood pressure in the lungs' arteries, and potentially leading to heart failure if not treated effectively. The advanced diagnostic methods, increased awareness, and aging population contribute to the rising prevalence of PAH. Veletri facilitates the treatment of this condition by boosting exercise capacity and retarding disease progression through vasodilation. As mentioned by the American College of Cardiology Foundation in October 2022, PAH affects roughly 15 to 30 individuals per million, making it a rare but significant condition. The proliferation of PAH is, thereby, stimulating the growth of the VELETRI market. Furthermore, the surge in venous diseases, a condition characterized by obstructed blood circulation in the veins, is poised to augment the VELETRI market's growth. The rising prevalence of this disease attributes to the aging population, inactive lifestyles, obesity, and enhanced diagnostic procedures. Veletri provides a solution to patients with venous diseases impacting the pulmonary vasculature by alleviating symptoms and increasing exercise tolerance. As highlighted in January 2025 by the Centers for Disease Control and Prevention, venous thromboembolism (VTE), a blood clot condition, affects approximately 900,000 individuals in the United States each year, with about 60,000 to 100,000 deaths annually due to VTE. Therefore, the VELETRI market is prospering due to the increasing prevalence of venous diseases.

Who Are the Dominant Players Across Different VELETRI Market Segments?
Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Actelion Pharmaceuticals Ltd., Euroapi S.A., United Therapeutics Corporation, Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Meitheal Pharmaceuticals Inc., Smiths Medical, Guangzhou Tosun Pharmaceutical Co. Ltd.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/veletri-global-market-report

Which Geographic Regions Are Expected to Dominate the VELETRI Market in the Coming Years?
North America was the largest region in the VELETRI market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the VELETRI Market?
2. What is the CAGR expected in the VELETRI Market?
3. What Are the Key Innovations Transforming the VELETRI Industry?
4. Which Region Is Leading the VELETRI Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.